Cardinal Health Maintains 2027 Investment Plan Versus 2026, Highlights Specialty Capacity Upgrades

Cardinal Health: Fiscal 2027 investment priorities vs. fiscal 2026, and where Specialty/Pharma capacity building is targeted

1) Fiscal 2027 investment priorities vs. fiscal 2026 (“more of the same,” but scaling)

Management framed fiscal 2027’s investment approach as continuing the same multiyear plan that has been in place for some time, emphasizing consistent execution of that plan rather than a change in investment focus. ¹

A. Where Cardinal says it “leaned in the most” (core priority areas)

In describing investments made organically and inorganically, management highlighted that the strongest “lean in” areas were:

• Specialty within other growth businesses
• M&A / the “M&A side”
• At-Home (including at-Home-related acquisitions like Strive/Adapt’s diabetes) ²

They also characterized these as faster-growing and more specialized market segments, typically with margins following growth and with markets described as fragmented (i.e., opportunity to scale and improve services). ²

B. Continued emphasis on operational excellence + adding scale/capabilities

Alongside growth investments, management emphasized “blocking and tackling” to improve the core, including operational metrics at/above all-time high levels, plus continued deployment of automation, technology, and advanced analytics across the distribution network. ³

Management also explicitly described fiscal 2027 as “more of the same” relative to fiscal 2026, but not to the same extent, with the M&A portion continuing to have some tailwind/benefit from deals done in 2026 (and “no material M&A” assumed for fiscal 2027). ⁴

C. Examples of what that means in practice (systems, automation, and service/capacity)

Cardinal connected investment priorities to both capacity and cost/service improvements:

• Specialty capacity constraints were described (e.g., refrigeration/freezing as bottlenecks; ambient easier to work through). ⁵
• Investment includes automation intended not only to create capacity but also to lower cost per order. ⁵
• They stated their service levels are at “levels that we’ve never had as an enterprise,” linking that to investing appropriately to avoid falling behind service expectations. ⁵
• In Specialty, fiscal 2026 performance was tied to scale and automation/capability execution, while they guided to continuation of Specialty as a key driver into fiscal 2027. ⁶

D. Guidance context: fiscal 2027 growth expected to continue supporting investment

While the question is about investment priorities, the company’s fiscal 2027 plan is consistent with continued investment because management expects segment growth and profit improvements that would be hard to achieve without ongoing operational and capacity investment:

• Cardinal guided fiscal 2027 EPS growth of 13% to 15% (EPS $12.40–$12.60). ⁷
• Within that, management expected Pharma segment revenue +3% to +5% and Pharma segment profit +8% to +11%, explicitly citing continued generic/brand strength and higher-margin growth in Specialty (upstream and downstream). ⁷
• For Specialty (as part of “Specialty within our other growth businesses”), they guided double-digit revenue growth in fiscal 2027, including contributions from new customers in Biopharma Solutions (organic + already announced inorganic efforts). ⁷

2) Capacity building in Specialty and Pharma: Kroger/existing customers vs potential new wins?

The transcript directly addresses this question: management was asked whether Specialty/Pharma capacity building is focused on Kroger and existing customers or whether the intent is to build capacity for potential new wins. ⁸

Management’s answer: don’t read it narrowly as just existing customers; it’s tied to “not being late” and long-term growth/service plans

Management responded that capacity building should not be interpreted narrowly; instead, it’s about ensuring they are not late versus customer demand/service requirements:

• “I would not read too much into that other than we are always looking to make sure we're not late.” ⁵
• They described capacity investment as tied to long-term planning and ensuring customers receive the service levels they expect, explicitly linking to their service-level record supported by appropriate investment. ⁵

Practical implication: primarily a service-level and bottleneck-driven capacity strategy, not a one-customer play

The company explained what capacity is constrained by and why it invests:

• Specialty bottlenecks are often refrigeration/freezing capabilities; ambient is easier. ⁵
• Investment includes automation to create capacity and reduce cost per order. ⁵
• They explicitly stated it is not “build-it-and-they-will-come”; it is “tied to the long-term plans” embedded in their growth plan to ensure service quality. ⁵

Kroger-specific note (Pharma stability), but not presented as the sole driver of capacity build

Kroger is mentioned as part of the customer renewal stability assumption within Pharma guidance:

• For planning, they stated they are assuming a “consistent book of business,” including a long-term extension with Kroger. ⁷

However, the capacity building interpretation they offered was broader (“not late” relative to long-term plans and bottlenecks), rather than framed solely around Kroger. ⁵

Bottom line

• Fiscal 2027 investment priorities vs. fiscal 2026: Cardinal framed fiscal 2027 as largely consistent with the same multiyear investment framework, emphasizing Specialty/other growth businesses, M&A/bolt-ons, and at-Home, while continuing heavy automation/technology/advanced analytics to improve core performance and service levels—described as “more of the same, but not to the same extent.” ¹²⁴
• Specialty/Pharma capacity building targeting: Management indicated capacity building is not only for Kroger/existing customers; it is part of a broader long-term plan to avoid being late and to address operational bottlenecks (e.g., refrigeration/freezing) and cost/service outcomes via automation—explicitly rejecting a simplistic “build-it-and-they-will-come” view. ⁸⁵